Cocrystal Pharma, Inc. COCP
Set alert
1.06 USD +0.07 +6.53%
At close · Nov 2
1.05 -0.01 -0.94%
After hours · Nov 2, 5:06 PM ET
1.03 Day range 1.07
0.76 52-week range 2.03
- YTD
- +8.16%
- 1 year
- -2.75%
- Open
- 1.03
- Prev close
- 0.995
- Mkt cap
- 20.42M
- Vol
- 13.82K
- Avg vol
- 58.02K
- EPS
- -0.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.03
- High
- 1.07
- Forward P/E
- -1.22
- Beta
- 1.45
- Short ratio
- 0.12
- Inst. own
- 6.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.96
- 200-d avg
- 1.91
- 1y target
- 8.00
5Y chart
Events in this range
- Oct 11, 2022Split: 1 for 12
- Oct 4, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Dec 4, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Jan 3, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Mar 20, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Mar 28, 2024Earnings: -0.44; estimate -0.57; surprise 22.81%
- Apr 4, 2024Rating: HC Wainwright & Co. · Buy → Buy
- May 13, 2024Earnings: -0.39; estimate -0.54; surprise 27.78%
- May 13, 2024Earnings: —; estimate -0.54; surprise —%
- May 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 14, 2024Earnings: -0.53; estimate -0.51; surprise -3.92%
- Aug 14, 2024Earnings: —; estimate -0.51; surprise —%
- Nov 13, 2024Earnings: -0.49; estimate -0.57; surprise 14.04%
Signals (101)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| MACD: Buy Signal | May 26, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 20, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| RSI: Overbought | Dec 23, 2024 | 1 year ago |
| SMA: Bullish | Dec 16, 2024 | 1 year ago |
| SMA: Bullish | Dec 16, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 11, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| SMA: Bearish | Oct 7, 2024 | 2 years ago |
| SMA: Bullish | Sep 30, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| RSI: Overbought | Jun 17, 2024 | 2 years ago |
| RSI: Overbought | Jun 3, 2024 | 2 years ago |
| SMA: Bullish | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| SMA: Bullish | Apr 1, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 19, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| SMA: Bearish | Dec 25, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| SMA: Bearish | Dec 4, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bearish | Nov 13, 2023 | 2 years ago |
| SMA: Bullish | Nov 6, 2023 | 2 years ago |
| MACD: Sell Signal | Sep 11, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| RSI: Oversold | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Nov 21, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 21, 2022 | 3 years ago |
| SMA: Bullish | Nov 14, 2022 | 3 years ago |
| RSI: Oversold | Oct 3, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 26, 2022 | 4 years ago |
| RSI: Oversold | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| RSI: Oversold | Jun 20, 2022 | 4 years ago |
| RSI: Oversold | Apr 25, 2022 | 4 years ago |
| SMA: Bearish | Apr 18, 2022 | 4 years ago |
| SMA: Bullish | Apr 11, 2022 | 4 years ago |
| SMA: Bearish | Mar 28, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 27.37M
- Enterprise value
- 6.02M
- Trailing P/E
- 0.00
- Forward P/E
- -1.22
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.04
- EPS (TTM)
- -1.84
- Beta
- 1.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -9.71M
- Total cash
- 18.14M
- Total debt
- 1.78M
- Return on equity
- -68.86%
- Shares outstanding
- 10.17M
- Short % of float
- 0.03%
- 50-day average
- 1.96
- 200-day average
- 1.91
Analyst view
Consensus: none
Price target (mean) 8.00 +654.7% upside
Now 1.06
- Target (low)
- 7.00
- Target (mean)
- 8.00
- Target (high)
- 10.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.56.
Financials — quick view
COCP Revenue — quarterly 0
COCP Net income — quarterly -3.16M
COCP EPS — quarterly -0.23
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.57 | -0.49 | +0.08 | +14.04% |
| Aug 14, 2024 | Jun 1, 2024 | -0.51 | -0.53 | -0.02 | -3.92% |
| Aug 14, 2024 | Jun 1, 2024 | -0.51 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.54 | -0.39 | +0.15 | +27.78% |
| May 13, 2024 | Mar 1, 2024 | -0.54 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -0.57 | -0.44 | +0.13 | +22.81% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 4, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 4, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cocrystalpharma.com
News
- Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
- Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
- Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K
- Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1b Data
- Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
- Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA)
- Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
- Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation
- Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And Influenza
- Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Your note
Sign in to keep a note on COCP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Oct 8, 2024 | 1,346,940 |
| HASSAN FRED | Director | Stock Award(Grant) | Oct 8, 2024 | 1,023,300 |
| JAPOUR ANTHONY J M.D. | Director | Stock Award(Grant) | Oct 8, 2024 | 14,924 |
| KORNBERG ROGER D | Director | Stock Award(Grant) | Oct 8, 2024 | 67,878 |
| LEE SAM | Chief Executive Officer | Stock Award(Grant) | Oct 8, 2024 | 76,355 |
| MARTIN JAMES JOSEPH | Chief Executive Officer | Stock Award(Grant) | Oct 8, 2024 | 40,569 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.71% | 275,656 | 741.51K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.28% | 130,028 | 349.77K | Sep 29, 2024 |
| Blackrock Inc. | 0.72% | 73,746 | 198.38K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.65% | 66,260 | 178.24K | Sep 29, 2024 |
| Morgan Stanley | 0.58% | 59,300 | 159.52K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.37% | 37,800 | 101.68K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.88% | 191,359 | 514.75K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 76,721 | 206.38K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 38,371 | 103.22K | Oct 30, 2024 |
| DFA U.S. Targeted Value Portfolio | 0.09% | 9,487 | 25.52K | Jul 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 8,667 | 23.31K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 8,526 | 22.93K | Oct 30, 2024 |